

# John M S Bartlett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2560910/publications.pdf>

Version: 2024-02-01

76  
papers

8,901  
citations

109137

35  
h-index

71532

76  
g-index

78  
all docs

78  
docs citations

78  
times ranked

10916  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incorporation of TILs in daily breast cancer care: how much evidence can we bear?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 147-162.	1.4	9
2	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	5.1	148
3	Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. <i>Clinical Cancer Research</i> , 2022, 28, 1871-1880.	3.2	11
4	Multi-omic machine learning predictor of breast cancer therapy response. <i>Nature</i> , 2022, 601, 623-629.	13.7	187
5	Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. <i>Current Oncology</i> , 2022, 29, 2599-2616.	0.9	5
6	Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study. <i>Journal of Clinical Pathology</i> , 2021, 74, 53-57.	1.0	15
7	Comparative survival analysis of multiparametric tests when molecular tests disagree A TEAM Pathology study. <i>Npj Breast Cancer</i> , 2021, 7, 90.	2.3	0
8	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 98.	2.3	4
9	Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa. <i>Npj Precision Oncology</i> , 2021, 5, 83.	2.3	4
10	Multisite verification of the accuracy of a multi-gene next generation sequencing panel for detection of mutations and copy number alterations in solid tumours. <i>PLoS ONE</i> , 2021, 16, e0258188.	1.1	8
11	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819.	3.0	319
12	Heterogeneity of Circulating Tumor Cell Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response. <i>Cancer Research</i> , 2021, 81, 6196-6206.	0.4	5
13	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
14	How current assay approval policies are leading to unintended imprecision medicine. <i>Lancet Oncology</i> , The, 2020, 21, 1399-1401.	5.1	34
15	Can immune markers help identify fast relapse in patients with muscle invasive bladder cancer?. <i>Pathology Research and Practice</i> , 2020, 216, 153200.	1.0	2
16	Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue Samples. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1246-1263.	1.2	5
17	A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination deficient Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5462-5476.	3.2	20
18	Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training. <i>PLoS ONE</i> , 2020, 15, e0238593.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	2.3	16
20	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	2.3	90
21	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
22	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
23	An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. <i>Modern Pathology</i> , 2019, 32, 59-69.	2.9	78
24	Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles. <i>Artificial Intelligence in Medicine</i> , 2019, 97, 27-37.	3.8	30
25	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. <i>Histopathology</i> , 2019, 75, 225-235.	1.6	74
26	Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts. <i>Journal of Pathology</i> , 2019, 247, 563-573.	2.1	63
27	Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. <i>PLoS Computational Biology</i> , 2019, 15, e1006596.	1.5	51
28	Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. <i>Clinical Cancer Research</i> , 2018, 24, 1344-1354.	3.2	414
29	Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy. <i>European Urology Focus</i> , 2018, 4, 740-748.	1.6	22
30	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2105-2122.	0.8	1,362
31	Pathway-based subnetworks enable cross-disease biomarker discovery. <i>Nature Communications</i> , 2018, 9, 4746.	5.8	30
32	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1364-1382.	1.2	644
33	Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 262-273.	1.3	43
34	Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival. <i>BMC Cancer</i> , 2018, 18, 750.	1.1	13
35	Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>Modern Pathology</i> , 2017, 30, 509-518.	2.9	32
36	HER2 status predicts for upfront AI benefit: TRANS-AIOG meta-analysis of 12,129 patients from AATAC, BIG 1-98 and TEAM with centrally determined HER2. <i>European Journal of Cancer</i> , 2017, 79, 129-138.	1.3	21

#	ARTICLE	IF	CITATIONS
37	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. <i>Npj Breast Cancer</i> , 2017, 3, 3.	2.3	17
38	Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>European Journal of Cancer</i> , 2017, 82, 219-227.	1.3	71
39	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper <sup>®</sup> . <i>Breast Cancer Research</i> , 2017, 19, 55.	2.2	29
40	ISOWN: accurate somatic mutation identification in the absence of normal tissue controls. <i>Genome Medicine</i> , 2017, 9, 59.	3.6	44
41	Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 774.	3.4	221
42	EMT in Breast Carcinoma—A Review. <i>Journal of Clinical Medicine</i> , 2016, 5, 65.	1.0	172
43	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw050.	3.0	166
44	Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 32-40.	1.3	36
45	Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies. <i>Scientific Reports</i> , 2016, 6, 29434.	1.6	13
46	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. <i>Npj Breast Cancer</i> , 2016, 2, 16014.	2.3	109
47	Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 66-74.	1.2	33
48	Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 16.	2.2	22
49	A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial. <i>Oncotarget</i> , 2016, 7, 49099-49106.	0.8	2
50	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-202.	1.3	53
51	Predicting Anthracycline Benefit: <i>TOP2A</i> and <i>CEP17</i> —Not Only but Also. <i>Journal of Clinical Oncology</i> , 2015, 33, 1680-1687.	0.8	55
52	An international study to increase concordance in Ki67 scoring. <i>Modern Pathology</i> , 2015, 28, 778-786.	2.9	195
53	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTEMIS): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 656-666.	5.1	114
54	A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials. <i>Oncotarget</i> , 2015, 6, 31693-31701.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Validated or Not Validated? That Is the Question. Journal of the National Cancer Institute, 2014, 106, djt360-djt360.	3.0	0
56	Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance. BMC Cancer, 2014, 14, 762.	1.1	16
57	Virtual tissue microarrays: a novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma <i>in situ</i> . Histopathology, 2014, 65, 2-8.	1.6	7
58	An International Ki67 Reproducibility Study. Journal of the National Cancer Institute, 2013, 105, 1897-1906.	3.0	498
59	Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. Breast Cancer Research and Treatment, 2013, 138, 773-781.	1.1	9
60	Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study. Journal of Clinical Oncology, 2012, 30, 4477-4484.	0.8	58
61	GSK3 $\beta$ and cyclin D1 expression predicts outcome in early breast cancer patients. Breast Cancer Research and Treatment, 2012, 136, 161-168.	1.1	47
62	Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. Journal of Pathology, 2012, 227, 481-489.	2.1	29
63	Expression of activated type I receptor tyrosine kinases in early breast cancer. Breast Cancer Research and Treatment, 2012, 134, 701-708.	1.1	3
64	Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 2011, 103, 1656-1664.	3.0	1,505
65	Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology, 2011, 29, 1531-1538.	0.8	160
66	Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet, The, 2011, 377, 321-331.	6.3	346
67	Quantification of Hormone Receptors to Guide Adjuvant Therapy Choice in Early Breast Cancer: Better Methods Required for Improved Utility. Journal of Clinical Oncology, 2011, 29, 3715-3716.	0.8	11
68	Biomarkers and Patient Selection for PI3K/Akt/mTOR Targeted Therapies: Current Status and Future Directions. Clinical Breast Cancer, 2010, 10, S86-S95.	1.1	26
69	A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon <i>HER2</i> FISH probe: intersite variation can be rigorously controlled using FISH. Histopathology, 2010, 56, 297-304.	1.6	8
70	Reply to V. Arena et al. Journal of Clinical Oncology, 2009, 27, e9-e10.	0.8	3
71	External Quality Assurance of HER2 FISH and ISH Testing. American Journal of Clinical Pathology, 2009, 131, 106-111.	0.4	35
72	Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial. Journal of Clinical Oncology, 2008, 26, 5027-5035.	0.8	90

#	ARTICLE	IF	CITATIONS
73	Determination of HER2 Amplification by In Situ Hybridization. American Journal of Clinical Pathology, 2008, 130, 920-926.	0.4	28
74	Recommendations for Collection and Handling of Specimens From Group Breast Cancer Clinical Trials. Journal of Clinical Oncology, 2008, 26, 5638-5644.	0.8	72
75	Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) "Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy. Journal of Clinical Oncology, 2007, 25, 4423-4430.	0.8	66
76	External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. Journal of Clinical Pathology, 2006, 60, 816-819.	1.0	35